STIMULATING TRANSPORT OF GLUCOSE INTO ANIMAL TISSUE BY THE ADMINISTRATION OF PINITOL

Abstract: Enhanced muscle performance, including strength, recovery and endurance, can be achieved by means of improved glucose transport and improved glycogen loading within animal muscle tissue, by administering an effective amount of a pinitol compound. Pinitol alone, or in combination with a synergistic amount of insulin, is effetive for controlling insulin-dependent diabetes.

Description: STIMULATING TRANSPORT OF GLUCOSE INTO ANIMAL TISSUE BY THE ADMINISTRATION OF PINITOL FIELD OF THE INVENTION The invention relates to the use of pharmaceuticals and dietary supplements to stimulate the transport of glucose into animal tissue, particularly muscle tissue. BACKGROUND One of the factors involved in the performance of muscle tissue, especially during such physical activities as prolonged exercise routines and athletic events, is the ability of the muscle tissue to transport sufficient amounts of glucose into the tissue and convert the glucose into useable energy (i.e., ATP). While a wide variety of products and techniques have been developed in an attempt to accelerate the growth and development of muscle tissue (i.e., increasing muscle mass), little activity has focused upon improving the performance of existing muscle tissue. SUMMARY OF THE INVENTION I have discovered that glucose transport and glycogen loading within animal tissue can be stimulated and enhanced by administering an effective amount of a pinitol compound. Such stimulated glucose transport and enhanced glycogen loading is particularly effective for enhancing the performance of muscle tissue. I have also discovered that pinitol alone, or in combination with a synergistic amount of insulin, is effective for controlling insulin-dependent diabetes. In summary, I have discovered: (i) a method of enhancing performance of muscle tissue comprising administering an effective amount of a pinitol compound, preferably pinitol, to a human desiring such enhanced performance, (ii) a method of increasing glycogen loading in human tissue, including muscle tissue, comprising administering an effective amount of a pinitol compound, preferably pinitol, to a human desiring such increased glycogen loading, (iii) a method of stimulating transport of glucose into human tissue, including muscle tissue, comprising administering an effective amount of a pinitol compound, preferably pinitol, to a nondiabetic human desiring such stimulated transport of glucose, and (v) a method of controlling insulin-dependent diabetes comprising administering an effective amount of a pinitol compound, preferably pinitol, with or without the conjoint administration of an effective amount of insulin, to an insulin-dependent diabetic. DETAILED DESCRIPTION OF THE INVENTION INCLUDING A BEST MODE Definitions As utilized herein, including the claims, the phrase performance of muscle tissue" means contraction of the muscle tissue so as effect movement of the body (e.g., running, smiling or throwing a bowling ball) or exertion against a counteracting force (e.g., holding a bowling ball against the force of gravity). As utilized herein, including the claims, the phrase "enhancing performance of muscle tissue" means (i) increasing the force with which the muscle tissue can contract (i.e., strength), (ii) decreasing the time required for the muscle tissue to recover after each contraction or series of contractions (i.e., recovery), and/or (iii) increasing the time period during which the muscle tissue can continuously or repetitively contract (i.e., endurance). As utilized herein, including the claims, the term "pinitol compound" means pinitol, metabolites of pinitol, derivatives of pinitol and mixtures thereof. As utilized herein, including the claims, the term "nondiabetic human" means a human who has NOT been diagnosed with non-insulin-dependent type II diabetes. As utilized herein, including the claims, the term "insulin-dependent diabetic" means a human who has been diagnosed with insulin-dependent type I diabetes. Active Ingredient Pinitol is available from a number of natural sources (such as pine needles, chick peas and soy beans). Pinitol can also be synthetically produced. One procedure for extracting pinitol from soy beans is disclosed in United States Patent No. 5,550,166, which is hereby incorporated by reference. A suitable grade of pinitol is also available from Humanetics Corporation under the mark Inzitol™. Various derivatives and metabolites of pinitol are also effective for enhancing the performance of muscle tissue by increasing glycogen loading within the muscle tissue and stimulating the transportation of glucose into the muscle tissue. A nonexhaustive listing of suitable derivatives and metabolites include pinitol glycosides, pinitol phospholipids, esterified pinitol, lipid-bound pinitol, pinitol phosphates and pinitol phytates. Administration ADMINISTRATION ROUTE The pinitol compound can be administered by virtually any of the commonly accepted practices for the administration of pharmaceutical preparations and dietary supplements including specifically, but not exclusively, mucosal administration, oral consumption, ocular administration, subcutaneous injection, transdermal administration, etc. Mucosal administration of the active ingredients includes such routes as buccal, endotracheal, nasal, pharyngeal, rectal, sublingual, vaginal, etc. For administration through the buccal/sublingual/pharyngeal/endotracheal mucosa, the pinitol compound may be formulated as an emulsion, gum, lozenge, spray, tablet or an inclusion complex such as cyclodextrin inclusion complexes. Nasal administration is conveniently conducted through the use of a sniffing power or nasal spray. For rectal and vaginal administration, the ingredients may be formulated as a cream, douche, enema or suppository. Oral consumption of the active ingredients may be effected by incorporating the ingredients into a food or drink, or formulating the ingredients into a chewable or swallowable tablet or capsule. Ocular administration may be effected by incorporating the active ingredients into a solution or suspension adapted for ocular application such as drops or sprays. Subcutaneous administration involves incorporating the active ingredients into a pharmaceutically acceptable and injectable carrier. For transdermal administration, the active ingredients may be conveniently incorporated into a lipophilic carrier and formulated as a topical creme or adhesive patch. DOSE RATE The range of dosages and dose rates effective for achieving the desired biological response may be determined in accordance with standard industry practices. As a general guide, a dose rate of about 0J to 1,000 mg of pinitol compound per kg body weight per day, preferably about 1 to 100 mg of pinitol compound per kg body weight per day, should provide the desired biological response of enhancing the performance of muscle tissue by increasing glycogen loading within the muscle tissue and stimulating the transportation of glucose into the muscle tissue. Such a range of dosages and dose rates are also generally applicable when the pinitol is administered, with or without the conjoint administration of insulin, to control insulin-dependent type I diabetes. EXPERIMENTAL Testing Protocol GLUCOSE UPTAKE Glucose transport was tested and measured in accordance with the protocol set forth in Amira Klip et al., Induction of Sugar Uptake Response to Insulin by Serum Depletion in Fusing Lβ Myoblasts, American Journal of Physiology, Vol. 247, No. 3, Part 1 (September 1984), herein incorporated by reference, except that the cell culture was preincubated for only 2 hours and the cells treated with varying concentrations of pinitol, insulin or a combination thereof as set forth in Tables One through Three. The raw data, in terms of "counts per minute" as measured with a scintillation counter, is provided in Tables One and Two. while calculated data, in terms of "pmol min "1 mg protein "1 ," is provided in Table Three. GLYCOGEN FORMATION The method for glycogen incorporation is similar to that of J Berger and NS Hayes, Anal Biochem. 261: 159-163 (1998), one of several standard references for radiolabeled (14-C) glucose incorporation into ethanol-precipitable glycogen. Into each well was added 1.25 ml of 1% TritonXlOO. The wells were then placed on a rotating agitator for 30 minutes to dissolve the cells. A 1 ml sample was removed from each well and placed in a 10 ml plastic tube. Into each sample was added 1 ml of a solution containing 18% trichloroacetic acid and 2mg/ml of glycogen (added as carrier). The treated samples were placed on ice for 20 minutes and then centrifuged for 10 minutes at 10,000 RPM with the supernatant transferred to new plastic tubes. The remaining solids were washed by adding 0.3 ml of the trichloracetic acid-glycogen solution to the pellet, and centrifuged again as before. The combined supernatants were added to 4 ml of ice cold ethanol and 0.25 ml of 2% sodium sulphate (to help precipitate glycogen, as in LN. Hung and L.A. Menahan, Biochemical Medicine, Vol. 24: 356-360 (1980)). This was left overnight at 4°C. The precipitate was collected the next day by centrifugation at 10,000 RPM for 10 min. The precipitate was redisolved in water (2 ml) and reprecipitated as before with ethanol and sodium sulphate. The precipitate was dissolved in water, added to scintillation fluid, and radioactivity determined. Results are reported in Tables Four and Five. Experiment One GLUCOSE UPTAKE (Concentration) TABLE ONE CONCLUSION: Pinitol alone does not meaningfully stimulate glucose transport at low concentrations (e.g., 0J4 mM), but can provide a significant stimulation in glucose transport at higher concentrations (e.g., 1.44 mM). Experiment Two GLUCOSE UPTAKE (Comparison of Pinitol, Insulin and Combination of Pinitol and Insulin) TABLETWO TABLE THREE CONCLUSION: Both pinitol and insulin, at higher concentrations, can provide a significant stimulation in glucose transport when administered alone, with the conjoint administration of pinitol and insulin, even at lower concentrations, providing a synergistic enhancement in glucose transport. Experiment Three GL YCOGEN FORMA TION (Comparison of Pinitol, Insulin and Combination of Pinitol and Insulin) TABLE FOUR TABLE FIVE CONCLUSION: Pinitol can provide a significant stimulation in glycogen formation when administered alone. The conjoint administration of pinitol with low levels of insulin (/ e , 10 "7 M) provides a synergistic enhancement in glycogen formation.

Claims: I Claim: 1. A method of enhancing performance of muscle tissue comprising administering an effective amount of a pinitol compound to a human desiring such enhanced performance. 2. The method of claim 1 wherein enhanced performance of muscle tissue is an increase in the strength of the muscle tissue. 3. The method of claim 1 wherein enhanced performance of muscle tissue is a decrease in recovery time of the muscle tissue. 4. The method of claim 1 wherein enhanced performance of muscle tissue is an increase in the endurance of the muscle tissue. 5. The method of claim 1 wherein the pinitol compound is pinitol. 6. A method of increasing glycogen loading in human tissue comprising administering an effective amount of a pinitol compound to a human desiring such increased glycogen loading. 7. The method of claim 6 wherein the pinitol compound is pinitol. 8. The method of claim 6 wherein the human tissue is muscle tissue. 9. A method of stimulating transport of glucose into human tissue comprising administering an effective amount of a pinitol compound to a nondiabetic human desiring such stimulated transport of glucose. 10. The method of claim 9 wherein the pinitol compound is pinitol. 11. The method of claim 9 wherein the human tissue is muscle tissue. 12. A method of controlling insulin-dependent diabetes comprising administering an effective amount of a pinitol compound to an insulin-dependent diabetic. 13. The method of claim 12 further comprising the conjoint administration of an effective amount of insulin to the insulin-dependent diabetic. 14. The method of claim 12 wherein the pinitol compound is pinitol.

Inventors: WEEKS CHARLES E, WEEKS, CHARLES, E.
Applicants: HUMANETICS CORP, WEEKS CHARLES E, HUMANETICS CORPORATION, WEEKS, CHARLES, E.
Application year: 2000
Main classification: A61K31
IPC codes: A61K31